Cocrystal Pharma, Inc. (NASDAQ:COCP) Stock Short Interest Falls 45.7%

Cocrystal Pharma, Inc. (NASDAQ:COCP) was the recipient of a significant decline in short interest in September. As of September 30th, there was short interest totaling 175,246 shares, a decline of 45.7% from the September 15th total of 322,748 shares. Based on an average daily volume of 54,337 shares, the short-interest ratio is currently 3.2 days. Approximately 1.5% of the company’s stock are short sold.

Cocrystal Pharma Stock Performance

Shares of NASDAQ:COCP traded down $0.03 during midday trading on Wednesday, hitting $1.05. 2,801 shares of the stock were exchanged, compared to its average volume of 815,898. The company has a market capitalization of $20.32 million, a PE ratio of -1.39 and a beta of 1.48. Cocrystal Pharma has a 52-week low of $0.76 and a 52-week high of $2.03. The business’s fifty day simple moving average is $1.13 and its two-hundred day simple moving average is $1.14.

Cocrystal Pharma (NASDAQ:COCP) last issued its earnings results on Thursday, August 13th. The company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.06). The business had revenue of $0.11 million during the quarter, compared to analysts’ expectations of $0.10 million. As a group, equities analysts anticipate that Cocrystal Pharma will post -0.69 EPS for the current year.

Analysts Set New Price Targets

Several research firms have weighed in on COCP. HC Wainwright reiterated a “buy” rating on shares of Cocrystal Pharma in a research note on Friday. Weiss Ratings downgraded shares of Cocrystal Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, August 21st. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold”.

About Cocrystal Pharma

Cocrystal Pharma, Inc is a clinical-stage biotechnology company focused on discovering and developing antiviral therapies. The company uses a structure-based drug discovery platform to identify small-molecule compounds designed to interfere with essential viral replication proteins.

Its research programs have targeted a range of viral diseases, including influenza A, norovirus and coronaviruses. Cocrystal’s development activities have included orally administered antiviral candidates intended for the treatment or prevention of viral infections, with programs advancing through a combination of preclinical research and clinical development.

Founded in 2007 and formerly known as BioZone Pharmaceuticals, the company adopted the Cocrystal Pharma name after combining with Cocrystal Discovery in 2015.